Pharmacologic and genetic manipulation of cell cycle regulators in CKD preclinical models, as well as human genetic data, suggest that reducing CDK4/6 activity, but not cyclin D1, may be a novel therapeutic strategy for treating CKD. Here, CDK4 is linked to chronic kidney disease.